Eight EIC-backed healthcare scaleups head to JP Morgan Healthcare Week 2026 as part of US soft-landing mission
- ›Eight EIC Accelerator-backed healthcare companies will join a US soft-landing mission to San Francisco from 7 to 15 January 2026 aligned with JP Morgan Healthcare Week.
- ›The mission is organised by the EIC Business Acceleration Services in partnership with the Global Scale-up Program and supported by Dealflow.eu with additional Dutch participants via Health Holland.
- ›Participating companies will receive investor introductions, pitch opportunities, market entry coaching and regulatory guidance aimed at accelerating US fundraising and commercialisation.
- ›This builds on a 2025 edition that participants said benefited from structured preparation and anchor events with US partners such as Wilson Sonsini, though attendance alone does not guarantee deals.
EIC healthcare companies to attend JP Morgan Healthcare Week 2026 in Silicon Valley
From 7 to 15 January 2026, eight European healthtech companies backed by the European Innovation Council Accelerator will travel to San Francisco to participate in a targeted US soft-landing mission timed around the JP Morgan Healthcare Conference. The mission is coordinated by the EIC Business Acceleration Services and run in partnership with the Global Scale-up Program. Dealflow.eu provides support and another six Dutch companies will join under the Dutch Health Holland internationalisation programme. The initiative aims to give selected European innovators direct exposure to the US investor and healthcare ecosystem at one of the sector's most concentrated gatherings.
Why JP Morgan Healthcare Week matters and what a soft-landing mission offers
Soft-landing can raise a company's visibility quickly. It does not however guarantee funding or market entry. Success depends on the quality of preparation, follow-up after the event and whether companies arrive with data and commercial milestones that meet US investor expectations.
Organisers, partners and preparation support
The mission is an EIC Business Acceleration Services activity in partnership with the Global Scale-up Program. Dealflow.eu provides promotional and operational support. Health Holland is bringing six additional Netherlands-based companies under its Global Scale-up programme. The Global Scale-up Program will prepare participants with investor readiness coaching and curated exposure to US venture capital funds, corporates and healthcare institutions. The delegation will also host a networking reception alongside Dutch and Swedish business delegations to increase cross-European visibility.
Participating EIC companies and their technologies
The press release names eight EIC-backed healthcare companies selected for the 2026 mission. Short descriptions follow and are drawn from company statements and available public material.
| Company | Country | Technology and focus |
| HBOX Therapies | Germany | Compact extracorporeal lung-assist platform designed to enable awake spontaneous breathing and faster recovery in respiratory failure patients. |
| Angiolutions | Germany | Device intended to halt early-stage abdominal aortic aneurysm growth offering a potential preventive treatment option. |
| ATRO Medical | Netherlands | Artimis® artificial meniscus for minimally invasive restoration of knee function and pain relief. |
| QurieGen | Netherlands | QuRIE-seq single-cell multiomics platform to map cellular responses and accelerate drug discovery and therapy development. |
| Capri Medical | Ireland | Implantable neurostimulation devices to treat chronic peripheral nerve pain with minimally invasive delivery. |
| Endoron Medical | Israel | Long-lasting sealing and fixation solution to improve outcomes in endovascular aneurysm repair procedures. |
| Delox | Portugal | Solid-peroxide bio-decontamination systems intended for healthcare, industry, biodefense and space environments. |
| Interlinked | Sweden | Intravenous therapy devices designed to prevent infusion damage and reduce side effects in oncology treatments. |
What the mission offers and the limits to be aware of
According to the organisers the EIC delegation will receive targeted investor introductions, pitch opportunities and business development meetings supported by strategic coaching on US market entry, fundraising and regulatory pathways. GSP will provide preparation and matchmaking to US venture capital funds, corporates and healthcare institutions. Networking receptions will broaden visibility for the European delegation.
A candid assessment is necessary. Large conferences consolidate attention but they are noisy. European companies often face additional hurdles in the US that go beyond introductions. Regulatory requirements such as FDA pre-submission interactions, device classifications and clinical trial expectations differ from EU pathways. Reimbursement and hospital procurement processes are also fragmented across payers and health systems. Investors typically look for clear clinical validation milestones, well defined regulatory routes and US commercial traction or local partnerships.
Lessons from 2025 and practical takeaways
The mission builds on the 2025 edition when 14 EIC-backed companies participated together with the Health Holland Global cohort. That programme staged anchor events with US partners such as the law firm Wilson Sonsini and supported entrepreneurs in navigating investor meetings and parallel industry forums. Participant feedback from 2025 highlighted the value of structured guidance, early preparation and coordinated outreach ahead of the conference.
For European scaleups planning such missions the pragmatic lessons are familiar. Prepare an investor narrative tailored to US audiences. Set clear objectives for meetings before arrival and schedule high value one-on-one interactions rather than relying on serendipity. Secure follow-up resources to continue conversations after returning to Europe. Bring concise clinical and commercial evidence that addresses US regulatory and payer questions.
How this fits within the EIC internationalisation ecosystem
The activity is part of the EIC Business Acceleration Services portfolio which includes international trade fair participation under the EIC International Trade Fairs Programme 3.0, investor readiness and outreach, procurement matchmaking and corporate partnership programmes. The EIC frames these interventions as a way to help awardees access global capital and partners at scale, a stated objective as the EIC seeks to boost commercialisation outcomes for deep tech and health innovators.
Next steps and how to follow the mission
The EIC Community platform publishes stories, open calls and event material related to the Business Acceleration Services. Companies interested in EIC BAS activities can sign up via the EIC Community and consult the EIC Service Catalogue for available support. Health Holland and the Global Scale-up Program publish separate information for participants joining under their schemes.
For mission outcomes it is reasonable to expect announcements of meetings, pitch events and perhaps follow-up financing news in the months after JP Morgan. However measurable success will depend on concrete commercial steps including term sheets, pilot agreements or regulatory milestones that are typically reported later.
A measured view
Programs like the EIC soft-landing missions provide valuable structure and introductions that many early stage companies cannot easily secure on their own. They can accelerate relationship building and surface opportunities. They are not a substitute for product readiness, clinical evidence and a long term go-to-market plan. Stakeholders including funders, public agencies and entrepreneurs should treat them as one useful element within a broader commercialisation strategy rather than a quick path to market dominance.
DISCLAIMER: The information about the mission is provided by the EIC in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission or other organisations. Participation in events does not guarantee investment or market access and individual outcomes will vary.